Tag: Nicox
Nicox: Extraordinary General Meeting 2022 – 07/08/2022 at 07:35
Nicox SA, an international company specializing in ophthalmology, informs its shareholders that the Extraordinary General Meeting convened on first call for Monday July 11, 2022 cannot deliberate for lack of…
Nicox: well oriented after a favorable publication – 07/07/2022 at 11:20
(CercleFinance.com) – Nicox gains more than 4% after the publication of new data on NCX 470 showing improvements in ocular hemodynamics and retinal cell physiology, in the Journal of Ocular…
Nicox Extraordinary General Meeting of July 11, 2022 – 06/22/2022 at 8:05 p.m.
Madam, Sir, Dear Shareholder, With this letter, we ask you to continue to provide Nicox with your valuable support by voting at the Extraordinary General Meeting convened for July 11,…
Nicox: the functions of president and CEO separated
(CercleFinance.com) – Nicox announced on Monday its intention to separate the functions of chairman of the board of directors and chief executive officer as part of the establishment of a…
Nicox: the functions of chairman and CEO separated – 05/16/2022 at 12:33
(CercleFinance.com) – Nicox announced on Monday its intention to separate the functions of chairman of the board of directors and chief executive officer as part of the establishment of a…
Nicox: phase 2 study published by the Journal of Glaucoma – 04/11/2022 at 12:08
(Photo credits: Pixabay – fernando zhiminaicela) (AOF) – Nicox jumped 10% to 1.84 euros. This morning, the company announced the publication of the results of the Dolomites Phase 2 clinical…
Nicox: Results of the Dolomites Phase 2 clinical study of NCX 470 published in the Journal of Glaucoma – 04/11/2022 at 07:40
Nicox today announces the publication of the results of the Phase 2 Dolomites clinical study of NCX 470 in patients with open-angle glaucoma or ocular hypertension in the Journal of…
Nicox: Orphan drug designation for Fera in the USA
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Nicox: the title jumps after a point on the Vyzulta
(CercleFinance.com) – Nicox shares jumped in volumes on Wednesday on the Paris Stock Exchange after a commercial point on Vyzulta, the treatment against glaucoma developed by the specialist in ophthalmology.…
Nicox: issuance of a new patent in China
(CercleFinance.com) – Nicox announced on Monday that a patent for NCX 470, its experimental glaucoma treatment, had been issued by Chinese authorities, extending product coverage to 2039. NCX 470, its…
Nicox: Issuance of a new patent in China
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Nicox: towards development in dry eye disease
(CercleFinance.com) – Nicox announces that future development of NCX 4251 will focus on dry eye disease, following encouraging post-hoc results from the Mississippi Phase 2b clinical study of NCX 4251…